STOCK TITAN
  1. Home
  2. News
  3. THRX

Theseus Pharmaceuticals, Inc. - THRX STOCK NEWS

Welcome to our dedicated page for Theseus Pharmaceuticals news (Ticker: THRX), a resource for investors and traders seeking the latest updates and insights on Theseus Pharmaceuticals stock.

Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) is a clinical-stage biopharmaceutical leader developing pan-variant kinase inhibitors to combat cancer treatment resistance. This page provides investors and researchers with essential updates on the company's clinical programs, strategic partnerships, and corporate developments.

Access comprehensive coverage of THRX announcements including trial progress for fourth-generation EGFR inhibitor THE-349, pipeline candidate nominations, and analysis of the Concentra Biosciences merger. Our curated news collection eliminates the need to track multiple sources for material updates affecting shareholder value.

Key content areas include: clinical trial milestones, financial performance updates, research collaborations, and regulatory filings. Stay informed about developments in NSCLC, CML, and GIST therapies while monitoring the company's extended cash runway through 2026.

Bookmark this page for real-time updates on Theseus' innovative approach to overcoming cancer resistance mechanisms. Check back regularly for verified press releases and objective analysis of events shaping the future of precision oncology therapeutics.

News

Theseus Pharmaceuticals Announces Closing of Tender Offer

Rhea-AI Summary
Theseus Pharmaceuticals, Inc. announces the successful completion of a tender offer by Concentra Biosciences, LLC, offering $4.05 per share in cash plus a contingent value right. The offer includes receiving 80% of net proceeds from certain programs and 50% of potential cost savings value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Concentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus Pharmaceuticals

Rhea-AI Summary
Concentra Biosciences, LLC and its subsidiary entered into a merger agreement with Theseus Pharmaceuticals, Inc. (Nasdaq: THRX) for a cash acquisition price of $3.90 to $4.05 per share, plus a non-tradeable contingent value right (CVR). The tender offer to acquire outstanding shares expires on February 13, 2024. 16,604,692 shares have been tendered, representing 37.2% of outstanding shares. The acquisition is expected to close in February 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
none
-
News

Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value Right

Rhea-AI Summary
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) has entered into a definitive merger agreement with Concentra Biosciences, LLC, whereby Concentra will acquire Theseus for a price per share of Theseus common stock of between $3.90 and $4.05 in cash, plus one non-tradeable contingent value right. The acquisition is expected to close in February 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.81%
Tags
acquisition
News

Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC

Rhea-AI Summary
Theseus Pharmaceuticals, Inc. (THRX) received unsolicited acquisition proposals from Foresite Capital, LLC and OrbiMed Advisors LLC, as well as Tang Capital Partners, LP on behalf of Concentra Biosciences LLC. Foresite and OrbiMed intend to explore acquiring all outstanding shares in a going-private transaction, while Concentra Biosciences proposed to acquire all outstanding shares for $3.80 per share in cash, plus a contingent value right representing the right to receive 80% of the net proceeds from any license or disposition of Theseus' programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.97%
Tags
none
-
News

Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives

Rhea-AI Summary
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) announced a strategic process to explore options for maximizing shareholder value, including a potential sale of assets, sale of the company, merger, or other strategic actions. The company also implemented a significant workforce reduction of approximately 72%, including the President of Research and Development. Theseus had cash, cash equivalents, and marketable securities of $225.4 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
50%
Tags
none
-
News

Theseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare Conference

Rhea-AI Summary
NASDAQ: THRX - Theseus Pharmaceuticals, Inc. to Participate in Fireside Chat at Stifel 2023 Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.49%
Tags
conferences
News

Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results

Rhea-AI Summary
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) reported business highlights and financial results for Q2 2023, including the advancement of lead candidate THE-349, a potential best-in-class fourth generation EGFR inhibitor. The company expects an IND submission for THE-349 in EGFR-mutant NSCLC in Q4 2023. Additionally, Theseus plans to nominate development candidates for BCR-ABL and next-generation KIT programs in H1 2024. The company also announced plans to explore the development of low dose THE-630 in mast cell-driven inflammatory indications. Theseus had $234.2 million of cash, cash equivalents, and marketable securities as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
earnings
-
News

Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST

Rhea-AI Summary
Theseus Pharmaceuticals discontinues development of THE-630 in GIST, prioritizes THE-349 for EGFR mutant lung cancer. $234 million in cash as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-72.06%
Tags
clinical trial
-
News

Theseus Pharmaceuticals to Participate in the Jefferies Healthcare Conference

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
conferences
News

Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.24%
Tags
clinical trial
Stock THRX logo
Theseus Pharmaceuticals, Inc.

Nasdaq:THRX

THRX Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

THRX Stock Data

181.28M
20.05M
2.56%
84.08%
0.9%
Biotechnology
Healthcare
Link
United States
Cambridge